Amg National Trust Bank adds Abbott Laboratories (ABT) to its portfolio

Abbott Laboratories (ABT) : Amg National Trust Bank added new position in Abbott Laboratories during the most recent quarter end. The investment management firm now holds 74,615 shares of Abbott Laboratories which is valued at $3,353,944 , the company said in a statement filed on Aug 3, 2016 with the SEC.Abbott Laboratories makes up approximately 0.29% of Amg National Trust Bank’s portfolio.

Other Hedge Funds, Including , Utah Retirement Systems boosted its stake in ABT in the latest quarter, The investment management firm added 1,400 additional shares and now holds a total of 268,803 shares of Abbott Laboratories which is valued at $12,082,695. Abbott Laboratories makes up approx 0.31% of Utah Retirement Systems’s portfolio.Courier Capital Corp boosted its stake in ABT in the latest quarter, The investment management firm added 125 additional shares and now holds a total of 28,944 shares of Abbott Laboratories which is valued at $1,301,033. Abbott Laboratories makes up approx 0.25% of Courier Capital Corp’s portfolio.Duff Phelps Investment Management Co reduced its stake in ABT by selling 620 shares or 3.14% in the most recent quarter. The Hedge Fund company now holds 19,110 shares of ABT which is valued at $855,173. Abbott Laboratories makes up approx 0.01% of Duff Phelps Investment Management Co’s portfolio.Stewart Patten Co boosted its stake in ABT in the latest quarter, The investment management firm added 40,071 additional shares and now holds a total of 276,584 shares of Abbott Laboratories which is valued at $11,796,308. Abbott Laboratories makes up approx 2.25% of Stewart Patten Co’s portfolio.Culbertson A N Co Inc boosted its stake in ABT in the latest quarter, The investment management firm added 4,145 additional shares and now holds a total of 99,879 shares of Abbott Laboratories which is valued at $4,191,922. Abbott Laboratories makes up approx 1.51% of Culbertson A N Co Inc’s portfolio.

Abbott Laboratories closed down -0.24 points or -0.53% at $45.02 with 76,57,947 shares getting traded on Monday. Post opening the session at $45.06, the shares hit an intraday low of $44.88 and an intraday high of $45.41 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.

On the company’s financial health, Abbott Laboratories reported $0.55 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Jul 20, 2016. Analyst had a consensus of $0.53. The company had revenue of $5333.00 million for the quarter, compared to analysts expectations of $5244.94 million. The company’s revenue was up 3.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.52 EPS.

Many Wall Street Analysts have commented on Abbott Laboratories. Abbott Laboratories was Upgraded by Edward Jones to ” Buy” on Jun 21, 2016.

Abbott Laboratories (Abbott) is engaged in the discovery development manufacture and sale of a range of health care products. Abbott operates in four business segments: Established Pharmaceutical Products Diagnostic Products Nutritional Products and Vascular Products. The Established Pharmaceutical Products segment includes the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment includes the sales of a line of adult and pediatric nutritional products. The Nutritional Products includes the sales of diagnostic systems and tests for blood banks hospitals commercial laboratories and alternate-care testing sites. The Vascular Products includes the sales of coronary endovascular structural heart vessel closure and other medical device products.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *